ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 42 of 131 for:    Recruiting, Not yet recruiting, Available Studies | "Burns"

Allogeneic ADSCs and Platelet-Poor Plasma Fibrin Hydrogel to Treat the Patients With Burn Wounds (ADSCs-BWs) (ADSCs-BWs)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03113747
Recruitment Status : Recruiting
First Posted : April 14, 2017
Last Update Posted : April 26, 2017
Sponsor:
Information provided by (Responsible Party):
A.A. Partners, LLC

Brief Summary:
The purpose of this study is to evaluate safety and efficacy of tissue engineered construct based on allogeneic cultured adipose-derived multipotent mesenchymal stromal cells (ALLO-ADSCs) and platelet-poor plasma fibrin hydrogel to treat patients with 2-B and 3- degree burn wounds

Condition or disease Intervention/treatment Phase
Second- or Third-degree Burns Biological: ALLO-ASCs Phase 1 Phase 2

Detailed Description:

For more than 20 years in clinical practice allogeneic transplantation of diploid fibroblasts (ADP) for burn wounds has been successfully used, it is used as an independent method, and a method of preparing wounds for autologous skin grafting [1].

The clinical efficacy of transplantation ADP, after the research done by E.V. Glushchenko; Rahayev AM [2,3] is not doubted.

Several studies have shown the efficacy of stem cells in promoting faster and superior wound healing. Alexaki [4] successfully used adipose derived mesenchymal stem cells in wound healing in mice and compared their effect with dermal fibroblasts. The application of stem cells in wounds promoted more efficient reepithelialization by their proliferative effect on keratinocytes.

In recent years, the world's leading burn centers attempted to restore the skin over large areas of burn wounds by epidermal layers transplantation of allogeneic cells cultured in culture medium.

The information expected in the study will be based on the principles of evidence-based medicine and will have practical significance for the treatment of burn wounds.

It is expected to show a positive effect of cultured multipotent mesenchymal stromal cells in the epithelization of burn wounds process as well as the extent and speed healing of skin flap during autologous skin grafting.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety and Efficacy Evaluation of Tissue Engineered Construct Based on Allogeneic Adipose-derived Multipotent Mesenchymal Stromal Cells and Platelet-poor Plasma Fibrin Hydrogel to Treat the Patients With Burn Wounds
Actual Study Start Date : March 25, 2015
Estimated Primary Completion Date : December 26, 2018
Estimated Study Completion Date : December 26, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: ALLO-ASCs
The patients receive ALLO-ADSCs. Biological is applied by surface application over perforated (1:3) autologous skin graft following the covering with hypoadhesive bandage. This procedure is carried out twice - once simultaneously with a skin grafting procedure and 2-3 days following autodermoplasty, while bandaging
Biological: ALLO-ASCs
1). Cryopreserved cell suspension of early passages of cultured allogeneic MSCs isolated from SVF obtained from lipoaspirate, a total of 10 mln. of cultured cells; 2).The TE-construct consisting of collagen- or fibrin-derived hydrogels and cells of early passages (up to P5) suspension of allogeneic cultured MSCs isolated from SVF obtained from lipoaspirate; Biological is applied by surface application over perforated (1:3) autologous skin graft following the covering with hypoadhesive bandage. This procedure is carried out twice - once simultaneously with a skin grafting procedure and 2-3 days following autodermoplasty, while bandaging.
Other Name: Allogeneic adipose-derived stem cells

No Intervention: The standard treatment

All patients will be subjected to standard stepped treatment of burn wounds:

  • Infusion therapy aimed to eliminate disorders of homeostasis during burn shock and burn toxemia;
  • Systemic antibiotic therapy for preventing infectious complications;
  • Adequate analgesia and sedation;
  • Decompression necrotomy in the first 24 hours following the burn trauma;
  • Necrectomy simultaneously with imposition of lyophilized xenografts performed in the first 1-5 days after applying burn;
  • Autologous skin grafting 3-5 days after performed xenografts with the perforation coefficient 1:3



Primary Outcome Measures :
  1. The degree of healing of skin flap; The degree of epithelialization of burn wounds in the perforations of a skin graft [ Time Frame: up to 1 month ]
    The degree of healing of skin flap after autologous skin grafting;


Secondary Outcome Measures :
  1. The dynamics of healing of skin flap [ Time Frame: up to 1 month ]
    Complete epithelization or epithelization more than 50% of the cells in the skin graft on the 10th day after autologous skin grafting are effective. The epithelialization less than 50% is not effective.

  2. Dynamics of the phagocytic activity of neutrophils in the area of burn wounds, according to NBT-test. [ Time Frame: up to 1 month ]
    Dynamics of the phagocytic activity of neutrophils in the area of burn wounds, according to NBT-test.

  3. Duration of treatment (days) to complete epithelialization of burn wounds; [ Time Frame: up to 1 month ]
    Duration of treatment (days) to complete epithelialization of burn wounds;



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and female aged 18-65 years;
  • Patients with 2-nd B and 3-d degree burn wound;
  • Body surface area involved in burns - from 10 to 50%;
  • The area of skin grafting - less than 6% of the skin surface;
  • Burn occurring within the 24 hours prior to the hospitalization;
  • Adequate antishock therapy in the prehospital phase;
  • Women of childbearing age to provide proof of a current, valid negative pregnancy test;
  • Confirmation of participation in the study by signing the Instrument of Consent, personally or through a responsible caretaker.

Exclusion Criteria:

  • Prognostically favorable or unfavorable outcome of the disease
  • (Lesion Severity Index, less than 30 or more, than 120 score);
  • Combined trauma;
  • Severe respiratory tract burn injuries;
  • Ischemic disease of the lower extremities;
  • The presence of cardiovascular disease (CVD): symptoms of unstable angina, myocarditis, heart disease, heart failure;
  • History of prior cancer;
  • Healing of duodenal or gastric ulcers in history;
  • Diabetes
  • Severe chronic liver diseases or kidney disease in history;
  • History of alcohol or other drug abuse;
  • Pregnanсy;
  • Any other physical diseases in decompensation or subcompensation,
  • or those that are rated as severe or moderate;
  • Therapeutic issues or psychiatric disorders of a patient which would
  • make the subject unsuitable to participate in this study or to complete it;
  • Participation in another clinical trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03113747


Contacts
Contact: Volodymyr S. Melnyk, MD, DSc +380679337461 V.Melnyk@ilaya.ua
Contact: Nataliia M. Olijnyk, PhD +380934040116 N.Olijnyk@ilaya.ua

Locations
Ukraine
The Kyiv City Clinical Hospital №2 Recruiting
Kyiv, Ukraine, 02094,13, Krakivska, str.,
Contact: Georgiy P. Kozynets, MD, PhD, DSc    +380973917611    dr.g.kozynets@gmail.com   
Contact: Nataliia M. Olijnyk, PhD    +380904040116    N.Olijnyk@ilaya.ua   
Sub-Investigator: Dmytro O. Zubov, PhD         
Sub-Investigator: Roman G. Vasyliev         
Sponsors and Collaborators
A.A. Partners, LLC
Investigators
Principal Investigator: Anatoliy V. Voronin The head doctor of The Kyiv City Clinical Hospital №2
Principal Investigator: Georgiy P. Kozynets, MD, PhD, DSc Head of the department of combustiology and plastic surgery, Shupyk National Medical Academy of Postgraduate Education

Additional Information:
Publications:
Responsible Party: A.A. Partners, LLC
ClinicalTrials.gov Identifier: NCT03113747     History of Changes
Other Study ID Numbers: MSC-P1
First Posted: April 14, 2017    Key Record Dates
Last Update Posted: April 26, 2017
Last Verified: April 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by A.A. Partners, LLC:
Allogeneic adipose-derived stem cells
burn wounds
wound healing
regeneration
repair
skin tissue engineering

Additional relevant MeSH terms:
Burns
Wounds and Injuries